Centessa Pharmaceuticals Plc Stock Price, News & Analysis

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that the FDA has granted Orphan Drug Designation for its drug candidate SerpinPC, aimed at treating hemophilia B. Registrational studies are set to commence in 4Q 2022. SerpinPC, designed to enhance thrombin generation, showed promising results in a Phase 2a study, demonstrating an 88% reduction in Annualized Bleeding Rate (ABR). The company also plans to release two-year follow-up data from the Phase 2a study in 4Q 2022, emphasizing the need for innovative treatment options.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced positive non-clinical pharmacokinetic and safety data for LB101, its first LockBody® candidate targeting solid tumors. The study showed systemic delivery of high doses of LB101 without hematological toxicity in non-human primates, indicating an improved therapeutic index and enhanced anti-tumor activity. The company plans to submit an Investigational New Drug (IND) application by late 2022, with management discussing the findings at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced participation in key investor conferences in September 2022. Notably, they will feature in the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, with a fireside chat at 8:45 AM ET in New York City. Following this, they will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 1:30 PM ET. Lastly, they will engage in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on September 28, 2022, at 11:30 AM ET. Live webcasts will be available on their website.

Centessa Pharmaceuticals (Nasdaq: CNTA) reported its Q2 2022 results, highlighting strong cash reserves of $484.2 million to fund operations into 2026. The firm plans to initiate registrational studies for SerpinPC in Hemophilia B by the end of 2022 and expects multiple clinical readouts across its pipeline over the next two years. However, it announced the discontinuation of ZF874 for Alpha-1 Antitrypsin Deficiency due to adverse events in early trials, concluding it would not achieve the desired profile.

Centessa Pharmaceuticals (Nasdaq: CNTA) has appointed Harris L. Rotman, PhD, as Senior Vice President of Regulatory Affairs. This leadership addition aligns with the company's initiative to advance its SerpinPC program in Hemophilia B into registrational studies this year. Dr. Rotman brings extensive experience from previous regulatory roles in various pharmaceutical companies. Centessa aims to deliver impactful medicines across rare diseases and immuno-oncology, supported by a robust R&D innovation engine.

Spotlight Therapeutics has appointed Antoine Yver, M.D., M.Sc., to its Board of Directors, enhancing its leadership with over 30 years of experience in drug development. Dr. Yver is recognized for his influential role in bringing significant cancer treatments like Enhertu, Tagrisso, and Lynparza to market. This strategic move aligns with Spotlight's mission to advance its TAGE platform for gene editing therapies aimed at various diseases. The company's growth trajectory is expected to benefit from Dr. Yver's expertise in oncology and immunology.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced the appointment of Mathias Hukkelhoven, Ph.D., to its Board of Directors, effective July 1, 2022. Hukkelhoven, with extensive experience in global regulatory and drug development, previously held leadership roles at Bristol Myers Squibb and Novartis. His expertise is expected to enhance Centessa's efforts in advancing its rare disease and immuno-oncology programs. Additionally, Aaron Kantoff resigned from the Board but will remain as an advisor. This leadership transition comes at a strategic time as the company aims to fulfill unmet medical needs.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced participation in two upcoming investor conferences. The first is the Jefferies Healthcare Conference, scheduled for June 9, 2022, featuring a fireside chat webcast at 4:30 PM ET. The second is the Goldman Sachs 43rd Annual Global Healthcare Conference on June 15, 2022, with a fireside chat at 8:00 AM PT / 11:00 AM ET. Live webcasts and archived recordings will be accessible in the investor relations section of the Centessa website.

Centessa Pharmaceuticals (CNTA) announced promising preclinical results for LB101, a PD-L1xCD47 LockBody, at the 2022 ASCO Annual Meeting. The data showed that LB101, delivered systemically as a single-agent, resulted in significant tumor regressions in a mouse model, with 26 out of 32 tumors eradicated. Importantly, no toxicity was observed, suggesting a favorable safety profile. The company plans to advance LB101 into clinical trials by late 2022, aiming to transform immuno-oncology treatments.